This issue of the ECDC Communicable Disease Threats Report (CDTR) covers the period 22-28 October 2023 and includes updates on poliomyelitis, SARS-CoV-2, West Nile virus, the Rugby World Cup 2023, and cryptosporidiosis cases.
ECDC and World Health Organization (WHO) Regional Office for Europe have jointly developed the European Respiratory Virus Surveillance Summary (ERVISS), an interactive surveillance data dashboard for influenza, respiratory syncytial virus (RSV), and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that also features a weekly epidemiological summary.
This issue of the ECDC Communicable Disease Threats Report (CDTR) covers the period 15-22 October 2023 and includes updates on respiratory virus epidemiology in the EU/EEA, SARS-CoV-2 variant classification, cryptosporidiosis, dengue, West Nile virus, and mass gathering monitoring for the Rugby World Cup.
This issue of the ECDC Communicable Disease Threats Report (CDTR) covers the period 8-14 October 2023 and includes updates on hepatitis A, influenza A(H5N1), COVID-19, the Rugby World Cup 2023, West Nile virus, measles and diphtheria.
Compared with the 2021‑2022 influenza season, for sentinel surveillance the number of tested specimens has
doubled, with a 4‑fold increase in influenza detections.
As autumn moves to winter, the WHO/Europe, EC and ECDC are issuing a clear, urgent message: people who remain unprotected against both COVID-19 and seasonal influenza – especially the most vulnerable and at-risk – should take up any offer for vaccination to prevent or mitigate the impact of these co-circulating respiratory infections.
This issue of the ECDC Communicable Disease Threats Report (CDTR) covers the period 1 - 7 October 2023 and includes updates on dengue, West Nile virus disease, COVID-19, chikungunya, Middle East respiratory syndrome, mpox, and mass gathering monitoring for the Rugby World Cup.
The public health advice-making process on schools in Sweden during the COVID-19 pandemic from November 2020 to April 2021 has undergone an After-Action Review (AAR), with results now available in a new report by ECDC and the Public Health Agency of Sweden, Folkhälsomyndigheten.